Investors of Mydecine Innovations Group received a pleasant surprise Tuesday morning, drawing coverage from a firm that is making itself known in the psychedelics industry.
Psychedelics
Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer
Novamind's new Chief Scientific Officer is a physician with deep knowledge of psychiatry and palliative care, including familiarity with ketamine-assisted psychotherapy.
Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study
Cybin completes its 51st pre-clinical molecule study, with four of these molecules already being advanced to toward clinical evaluations.
Atai IPO Day An Underwhelming Event
The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.
Texas Will Study Benefits Of Psychedelics For Military Veterans Under Bill Enacted Without Governor’s Signature
The governor of Texas allowed a bill that will require the state to study the therapeutic potential of psychedelics to become law without his signature on Friday.
Rainbo’s Tonya Papanikolov Believes in the Magic of Mushrooms
Tonya Papanikolov could talk about mushrooms for hours.
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE announces two, new ketamine-based treatment protocols: one for pain and one for depression. These new protocols will be distributed via iSTRYM.
Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004
Cybin's latest R&D initiative (CYB004) is a proprietary molecule targeting anxiety disorders.
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Mydecine announces a new program to incorporate AI "machine learning" into its drug R&D.
Bright Minds Biosciences Announces Application to List on Nasdaq
Bright Minds Biosciences has applied to uplist to the NASDAQ.
It Begins: Bill Introduced Into Congress To Decriminalize All Drugs
A bill to decriminalize drug possession has been introduced into Congress. If passed, jurisdiction for drug classifying would move from the Justice Department to the Department of Health and Human Services.
Creso Pharma and Red Light Holland Merge to Introduce The HighBrid Lab (TM), a Leading Global Psychedelics x Cannabis Company, Specializing in Recreational Products, Applied Science, Technology and Innovation
Red Light Holland and ASX-listed Creso Pharma are merging to form HighBrid Lab. TRIP CEO Todd Shapiro to lead the combined entity.
Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound
Field Trip completes another preliminary step toward its Phase I clinical trial of FT-104.
Atai To Upsize IPO Financing To $246 Million, The Industry Leader Just Got Bigger
Atai Life Sciences has re-filed with the SEC to increase its IPO financing from $100 to $246 million. It's a big deal.